Design of a multi-epitope peptide vaccine candidate against chandipura virus: an immuno-informatics study

Pavitrakar, Daya V; Atre, Nitin M; Tripathy, Anuradha S.; Shil, Pratip

doi:10.1080/07391102.2020.1816493

Cited by 8 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, some TLR2 and TLR4 agonists have been used in peptide-based vaccines against infectious diseases, including TB, such as TLR2 agonists ESAT6 (144), phenol-soluble modulin a4 (PSMa4) (145), dipalmitoyl-S-glyceryl cysteine (Pam2Cys) (115,146), and PorB (147,148), TLR4 agonists RpfE (Rv2450c) (149), 50S ribosomal protein L7/L12 (RplL) (22,(150)(151)(152)(153)(154)(155), heparin binding hemagglutinin (HBHA) (156), cholera toxin subunit B (CTB) (157)(158)(159), and RS-09 (160,161). In addition, helper peptides and antimicrobial peptides are also used to construct peptide-based vaccines to enhance their immune effects, such as PADRE (148) (151) (156), Hsp70 (161), TR-433 (161), human bdefensin 1 (HBD-1) (162), HBD-2 (163), HBD-3 (19,(164)(165)(166)(167), and Griselimycin (84). The amino acid sequences of the mentioned helper peptides can be found in Table 2.…”

Section: Tlr Agonists and Helper Peptidesmentioning

confidence: 99%

Peptide-Based Vaccines for Tuberculosis

Gong

Pan²,

Cheng

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. As a result of the coronavirus disease 2019 (COVID-19) pandemic, the global TB mortality rate in 2020 is rising, making TB prevention and control more challenging. Vaccination has been considered the best approach to reduce the TB burden. Unfortunately, BCG, the only TB vaccine currently approved for use, offers some protection against childhood TB but is less effective in adults. Therefore, it is urgent to develop new TB vaccines that are more effective than BCG. Accumulating data indicated that peptides or epitopes play essential roles in bridging innate and adaptive immunity and triggering adaptive immunity. Furthermore, innovations in bioinformatics, immunoinformatics, synthetic technologies, new materials, and transgenic animal models have put wings on the research of peptide-based vaccines for TB. Hence, this review seeks to give an overview of current tools that can be used to design a peptide-based vaccine, the research status of peptide-based vaccines for TB, protein-based bacterial vaccine delivery systems, and animal models for the peptide-based vaccines. These explorations will provide approaches and strategies for developing safer and more effective peptide-based vaccines and contribute to achieving the WHO’s End TB Strategy.

show abstract

Section: Tlr Agonists and Helper Peptidesmentioning

confidence: 99%

Peptide-Based Vaccines for Tuberculosis

Gong

Pan²,

Cheng

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Several multiepitope vaccines have been reported previously that employed immunoinformatics approaches with promising results against SARS-CoV-2 [71], Chandipura virus [72], HIV [73], Nipah virus [74], Ebola virus [75], Zika virus [76], and so on. In this study, a multiepitope vaccine construct containing B-cell, CTL, and HTL epitopes linked to an adjuvant and linkers was designed that could effectively provoke the host's innate and adaptive immune responses, proposing it to be a strong candidate for the BEFV vaccine development approach.…”

Section: Discussionmentioning

confidence: 99%

Immunoinformatics Approach to Design Multi-Epitope- Subunit Vaccine against Bovine Ephemeral Fever Disease

et al. 2021

View full text Add to dashboard Cite

Bovine ephemeral fever virus (BEFV) is an overlooked pathogen, recently gaining widespread attention owing to its associated enormous economic impacts affecting the global livestock industries. High endemicity with rapid spread and morbidity greatly impacts bovine species, demanding adequate attention towards BEFV prophylaxis. Currently, a few suboptimum vaccines are prevailing, but were confined to local strains with limited protection. Therefore, we designed a highly efficacious multi-epitope vaccine candidate targeted against the geographically distributed BEFV population. By utilizing immunoinformatics technology, all structural proteins were targeted for B- and T-cell epitope prediction against the entire allele population of BoLA molecules. Prioritized epitopes were adjoined by linkers and adjuvants to effectively induce both cellular and humoral immune responses in bovine. Subsequently, the in silico construct was characterized for its physicochemical parameters, high immunogenicity, least allergenicity, and non-toxicity. The 3D modeling, refinement, and validation of ligand (vaccine construct) and receptor (bovine TLR7) then followed molecular docking and molecular dynamic simulation to validate their stable interactions. Moreover, in silico cloning of codon-optimized vaccine construct in the prokaryotic expression vector (pET28a) was explored. This is the first time HTL epitopes have been predicted using bovine datasets. We anticipate that the designed construct could be an effective prophylactic remedy for the BEF disease that may pave the way for future laboratory experiments.

show abstract

“…The study of peptide-based vaccinations has grown in popularity. Long peptides with immunodominant epitopes may be employed as vaccines if they can stimulate both humoral and cellular immunity against a variety of serological types (23,24). The terms "multivalent" and "multivalent vaccine" are frequently used imprecisely to refer to two distinct vaccine types (25): one that may provide protection against numerous illnesses with a single vaccine and one that can provide protection against multiple strains of a single pathogen (25)(26)(27).…”

Section: Introductionmentioning

confidence: 99%

Development of a Novel Bivalent Vaccine Candidate against Hepatitis A Virus and Rotavirus Using Reverse Vaccinology and Immunoinformatics

Yarmohammadi,

Sepahi,

Hamidi-fard

et al. 2024

Preprint

View full text Add to dashboard Cite

Hepatitis A virus (HAV) and rotavirus are mainly transmitted through fecal-oral and person-to-person contact, which cause severe gastrointestinal complications and liver diseases. This work used reverse vaccinology and immunoinformatic methods to create a novel bivalent vaccination against the rotavirus and HAV. The amino acid sequences of HAV-rotavirus proteins (VP1 and VP8*) were retrieved from GenBank. Multi-epitope DNA structures. Various computational approaches were employed to predict highly conserved regions and the most immunogenic B-cell and T-cell epitopes of VP8 and VP1 of rotavirus and HAV proteins in both humans and BALB/c. Moreover, the predicted fusion protein was analyzed regarding primary and secondary structures and homology validation. In this study, we used two highly conserved peptide sequences of VP8 and VP1 of rotavirus and HAV that induce T and B cell immunogenicity. According to T-cell epitope prediction, this area comprises 2713 antigenic peptides for HLA class II and 30 HLA class I antigenic peptides, both of which are virtually entirely conserved in the Iranian population. In this study, validation as well as analysis of the secondary and three-dimensional structure of the VP8*-rotavirus + AAY + HAV-VP1 fusion protein, with the aim of designing a multi-epitope vaccine with different receptors such as complications. TLR), 3,4 high immunogenic binding ability with immunological properties and interaction between multi-epitope target and TLR receptors were predicted, and it is expected that the target protein fusion has stable antigenic potency and compatible half-life. The above is suggested as universal vaccination programs.

show abstract

Design of a multi-epitope peptide vaccine candidate against chandipura virus: an immuno-informatics study

Cited by 8 publications

References 47 publications

Peptide-Based Vaccines for Tuberculosis

Peptide-Based Vaccines for Tuberculosis

Immunoinformatics Approach to Design Multi-Epitope- Subunit Vaccine against Bovine Ephemeral Fever Disease

Development of a Novel Bivalent Vaccine Candidate against Hepatitis A Virus and Rotavirus Using Reverse Vaccinology and Immunoinformatics

Contact Info

Product

Resources

About